This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2025 Apr 1;161(4):355-357.

doi: 10.1001/jamadermatol.2025.0049.

The Evolving Landscape of Biologics-Biosimilars, Biobetters, and Bioparallels

Ivo Abraham^{1

2

3}, Karen MacDonald¹

Affiliations

Affiliations

¹ Matrix45, LLC, Tucson, Arizona.
² Department of Pharmacy, Practice, and Science and Center for Health Outcomes and Pharmacoeconomic Research, R. Ken Coit College of Pharmacy, University of Arizona, Tucson.
³ Associate Editor for Quantitative Methods, JAMA Dermatology.

PMID: 40042861
DOI: 10.1001/jamadermatol.2025.0049

The Evolving Landscape of Biologics-Biosimilars, Biobetters, and Bioparallels

Ivo Abraham et al. JAMA Dermatol. 2025.

. 2025 Apr 1;161(4):355-357.

doi: 10.1001/jamadermatol.2025.0049.

Authors

Ivo Abraham^{1

2

3}, Karen MacDonald¹

Affiliations

¹ Matrix45, LLC, Tucson, Arizona.
² Department of Pharmacy, Practice, and Science and Center for Health Outcomes and Pharmacoeconomic Research, R. Ken Coit College of Pharmacy, University of Arizona, Tucson.
³ Associate Editor for Quantitative Methods, JAMA Dermatology.

PMID: 40042861
DOI: 10.1001/jamadermatol.2025.0049

No abstract available

PubMed Disclaimer

Comment in

Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis.
Phan DB, Bewley AP, Laws P, Mackenzie T, Smith CH, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN. Phan DB, et al. JAMA Dermatol. 2025 Apr 1;161(4):358-366. doi: 10.1001/jamadermatol.2025.0055. JAMA Dermatol. 2025. PMID: 40042863

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems